New meningitis b vaccine enters human testing
NCT ID NCT07395739
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This early-stage trial is testing a new vaccine called DX-104 to see if it is safe and triggers an immune response against group B meningococcal bacteria, which can cause meningitis. The study involves 30 healthy adults aged 18 to 50 who will receive either the new vaccine or an existing one. Researchers will monitor for side effects and measure antibody levels in the blood.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Group B Meningococcal OMV Vaccine (DX-104)
- What this could lead to
- If successful, this could lead to a new vaccine option to prevent meningitis B infection.
- What could go wrong
- This is a very early Phase 1 trial with only 30 participants, so safety and immune response are still uncertain. The vaccine may not work as well as existing options or could have unexpected side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEISSERIA MENINGITIDIS SEROGROUP B are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Linear Early Phase Limited
RECRUITINGPerth, Western Australia, 6009, Australia